Phost’in Therapeutics and the Gianni Bonadonna Foundation announce First Patients Dosed with the First-In-Class PhOx430 in an adaptive Phase I/II in patients with Advanced Solid Tumors

Montpellier, France – September 2022, 14th Phost’in Therapeutics (Montpellier, France), a clinical stage company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, today announced dosing of the first three patients in the Dose Escalation phase of the PhAST trial, an adaptive Phase I/II study in patients with advanced solid tumors evaluating the First-In-Class selective N-glycosylation inhibitor, PhOx430. The study is operated with the scientific contribution of the Gianni Bonadonna Foundation which collaborated to the conception of the research protocol. Download the full Press Release

The release as fetched from its publisher. phostin.com ↗